Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rematin LIV
- Development stage
- Unknown
- Lead developer
- Waterley Pharmaceuticals
- Modality
- Peptides, Small Molecules
- Administration
- Oral
01
Overview
Rematin LIV is an oral nutritional supplement developed by Waterley Pharmaceuticals, specifically designed for liver support and the management of hepatology-related conditions such as hepatic encephalopathy and sarcopenia. The product is formulated as a powder containing a blend of whey protein and high-dose branched-chain amino acids (BCAAs), including L-leucine, L-isoleucine, and L-valine. It is further enriched with L-carnitine, L-taurine, medium-chain triglycerides (MCT), and docosahexaenoic acid (DHA), along with a comprehensive profile of essential vitamins. Rematin LIV aims to improve nitrogen balance, reduce ammonia levels, and support muscle protein synthesis in patients with chronic liver disease. The supplement is lactose-free, gluten-free, and contains no added sucrose, making it suitable for patients with specific dietary restrictions and metabolic needs associated with liver dysfunction.
- Brand names
- Rematin LIV
02
Targets
mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on Rematin LIV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rematin LIV.